Editors' (re)View

Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.

Articles

editreview
While macroeconomic uncertainty weighs on the sector, there are glimmers of hope in some areas of pharmaceutical outsourcing and services.
editreview
While the process has been a buzzword for years, offering an alternative to traditional batch manufacturing, industry uptake has been slow. However, the tide may be turning.
editreview
The Tar Heel State’s decades-long focus on economic development in life sciences and pharma manufacturing is bearing fruit, as it looks to rival the Bay Area and Boston.
editreview
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
editreview
The threat of tariffs on pharmaceuticals and “most favored nation” drug pricing are weighing on the sector as biotech funding continues to dry up.
editreview
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
editreview
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
editreview
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
editreview
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
editreview
The industry got a reprieve as pharmaceuticals were exempted from President Trump’s reciprocal tariffs announced this week. However, analysts expect it to be short-lived.
editreview
This week, President Donald Trump doubled down on his threat to target the pharma industry with tariffs meant to bring drug manufacturing back to the United States.
editreview
Major players in the contract development and manufacturing organization industry gathered in New York City this week to provide updates on their infrastructure investments.
editreview
Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.
editreview
It’s been a topsy-turvy week for President Trump’s tariff proclamations, which have created anxiety and confusion for businesses that rely on trade with Canada and Mexico.
editreview
The Indiana-headquartered pharma giant chose to make its investment announcement this week in Washington, D.C., with newly confirmed Commerce Secretary Howard Lutnick.